Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06332781 · ClinicalTrials.gov registry record · Phase 4
Intravesical Gentamicin to Prevent Recurrent UTI
A Phase 4 study of Recurrent Uti, sponsored by Women and Infants Hospital of Rhode Island.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06332781 is a Phase 4 study of Recurrent Uti that is actively recruiting participants, run by Women and Infants Hospital of Rhode Island. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06332781, a Phase 4 study of Recurrent Uti, is actively recruiting participants, sponsored by Women and Infants Hospital of Rhode Island.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Feasibility assessment of intravesical gentamicin instillation (putting antibiotics directly into the bladder) versus the current standard of care of oral nitrofurantoin prophylaxis (taking a low dose of antibiotics by mouth every day) to prevent recurrent urinary tract infections (UTI)
Conditions Studied
Interventions
- DRUG Nitrofurantoin
- DRUG Gentamicin
Study Locations (1)
Rhode Island
- Women & Infants Hospital - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-04-28 |
| Est. Completion | 2026-05-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06332781
The ClinicalTrials.gov registry entry for NCT06332781 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Women and Infants Hospital of Rhode Island, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Recurrent Uti appearing as the primary indexed condition, and to 2 interventions - of which Nitrofurantoin is the first listed.
NCT06332781 reports 1 study location spanning 1 distinct geographic area - top geographies include Rhode Island.
Frequently Asked Questions
What is clinical trial NCT06332781 about?
NCT06332781 is a clinical study titled "Intravesical Gentamicin to Prevent Recurrent UTI". Feasibility assessment of intravesical gentamicin instillation (putting antibiotics directly into the bladder) versus the current standard of care of oral nitrofurantoin prophylaxis (taking a low dose of antibiotics by mouth every day) to prevent recurrent urinary tract infections (UTI)
What is the current status of trial NCT06332781?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2025-04-28. Estimated completion is 2026-05-31.
What conditions does trial NCT06332781 study?
This clinical trial studies the following conditions: Recurrent Uti.
What interventions are being tested in trial NCT06332781?
The interventions under investigation include: Nitrofurantoin (DRUG), Gentamicin (DRUG).
Who is sponsoring clinical trial NCT06332781?
This trial is sponsored by Women and Infants Hospital of Rhode Island, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06332781 being conducted?
This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Uti
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.